Sodium–glucose cotransporter-2 inhibitors have become key therapeutic agents in the management of heart failure , yet direct comparisons of their clinical effectiveness remain limited. To address this gap, a study evaluated outcomes associated with dapagliflozin and empagliflozin use in patients diagnosed with heart failure , involving 4,930 patients, mean age, 68.8 years.
Over a median follow-up of 16 months, the study found no significant difference between dapagliflozin and empagliflozin in the primary composite outcome of cardiovascular death or heart failure hospitalization, which occurred in 9.8% of patients receiving dapagliflozin and 9.3% of those receiving empagliflozin (adjusted hazard ratio [AHR] 0.99). Similar results were observed across left ventricular ejection fraction subgroups, including LVEF ≤40%, 41%–49%, and ≥50%, with no significant between-group heterogeneity.…
